Aminex Therapeutics, Inc. Closes $4M Series A Financing
Company Also Appoints Stacy Hock and Rhonda Rhyne to Board of Directors
Company Also Appoints Stacy Hock and Rhonda Rhyne to Board of Directors
KIRKLAND, Wash., Nov. 9, 2015 /PRNewswire/ -- Aminex Therapeutics, Inc., which has developed a first-in-class suppressor cell modulator cancer immunotherapy, today announced it has completed a $4 million Series A financing, including fifteen new shareholders. Concurrent with the financing, Stacy Hock and Rhonda Rhyne have been appointed to the Aminex Board of Directors.
"We are very encouraged by the positive response from investors. It is a reflection of our progress to date and our transformational opportunities," stated Jim Skaggs, chief executive officer and chairman of Aminex Therapeutics. "The proceeds will be used to finalize Aminex's preclinical testing and prepare for Phase 1/2A human clinical trials to start midyear 2016. Our patented AMX-513 combination therapy enables the immune system to attack cancer by regulating myeloid-derived suppressor cells."
Skaggs added, "We are also excited to strengthen our board with Stacy Hock and Rhonda Rhyne." Ms. Hock is co-owner of Hock, LLC, and manager of the Joel and Stacy Hock Charitable Fund. She serves on a number of boards and previously held senior management positions with IBM. Ms. Rhyne is a clinical pharmacist and medical technology industry leader who has spent the past 20 years in executive management for life science companies. She specializes in taking innovative technologies from the research bench to successful commercialization and was awarded Ernst & Young Entrepreneur of the Year for Medical Technology, San Diego.
About Aminex Therapeutics, Inc.
Aminex Therapeutics, Inc. is a drug development company focused on discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies which enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease rising costs of cancer therapy.
For more information, please visit www.aminextx.com.
Logo - http://photos.prnewswire.com/prnh/20151108/285010LOGO
SOURCE Aminex Therapeutics, Inc.
Share this article